Yahoo
NasdaqGS - Delayed Quote USD

Savara Inc. (SVRA)

5.37 0.00 (0.00%)
At close: September 4 at 4:00:00 PM EDT
5.39 +0.02 (+0.37%)
After hours: September 4 at 7:30:01 PM EDT
Trade Savara on Coinbase
Chart Range Bar
Loading chart for SVRA
  • Previous Close 5.37
  • Open 5.32
  • Bid 3.87 x 200
  • Ask 6.87 x 200
  • Day's Range 5.31 - 5.39
  • 52 Week Range 3.34 - 7.01
  • Volume 625,206
  • Avg. Volume 1,796,251
  • Market Cap (intraday) 1.103B
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) --
  • EPS (TTM) -0.58
  • Earnings Date (est.) Nov 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.94

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

www.savarapharma.com

70

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SVRA
10.95%
S&P 500 (^GSPC)
12.75%

1-Year Return

SVRA
50.00%
S&P 500 (^GSPC)
18.71%

3-Year Return

SVRA
39.84%
S&P 500 (^GSPC)
70.93%

5-Year Return

SVRA
246.45%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -32.24M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

9.00
10.94 Average
5.37 Current
16.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 12/23/2025
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 8 -> 10

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -50.15%

  • Return on Equity (ttm)

    -105.48%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -139.31M

  • Diluted EPS (ttm)

    -0.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    174.82M

  • Total Debt/Equity (mrq)

    21.17%

  • Levered Free Cash Flow (ttm)

    -57.19M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: